David W. Lim

A pleasure having Professor @oesterreichs from @UPMCHillmanCC @UPMC @PittTweet @MageeWomens visit us @WCHospital today and discussing #research collaborations in #lobular #breastcancer #bcsm @LobularBCA

The 2026 @UofTGSx Update in General Surgery is almost here. As Program Chair, I am proud of the program we’ve put together. Guess what?! I’ll be taking about difficult gallbladders! Amazing speakers, how I do it sessions, and hot topics. Join us Apr 15-18 cpd.utoronto.ca/generalsurgery/

Enjoyed all the great science and seeing friends and colleagues at @SocSurgOnc #SSO2026! Congrats to to Rina Lee, medical student at @uoftmedicine, for winning a Top-Rated Poster Award for her quickshot looking at nodal burden among patients with T1-T2 HR+/HER2- #breastcancer

Enjoyed speaking at the Journée scientifique sur la #reconstruction du sein oncologique in #Montréal, organized by l’Association des spécialistes en chirurgie plastique et esthétique du Québec, and seeing familiar faces. #ASCPEQ #breastcancer #bcsm #plasticsurgery

Great start to day 1 of our breast cancer survivorship and supportive care conference!

Enjoyed all the poster presenters and co-moderating the panel on “Addressing the Unique Needs of LGBTQ+ in Breast Cancer Survivorship” at the international #breastcancer #survivorship @BCSurvivorConf with @GaryKoMD @RadOnculous Margo Kennedy Christian Schulz-Quach Alphonse Daniel

We had a great first panel highlighting “Post-surgical functional impairment” at the 1st #intermational #breastcancer #survivorship and #supportivecare #conference @BCSurvivorConf with speakers @DrToniZhong @MargieMcNeely Dr Emma Mauti, patient advocate Michelle Audoin #bcsm

Packed room for the 1st International #breastcancer #survivorship and #supportivecare #conference opened by @munasaid44 . @BCSurvivorConf Excited for the next 2 days of learning @jjonestoronto @uoftcpd @UofTSurgery

Looking forward to moderating these exciting sessions at the #BreastCancer Survivorship @BCSurvivorConf this week in Toronto! 🍁 Join the 300 attendees attending this Friday and Saturday 👇🏻 📆 November 28-29, 2025 📍The Westin Harbour Castle 🇨🇦 🔗breast-survivorship-conference.ca #bcsm

Really proud of all the undergrad and MD summer research students who joined my lab @WCHospital this summer and presenting their work at @UofTIMS SURP Research Day and @WCHResearch summer student research day! Was a pleasure working with you all this summer!

Great to see #lobular #ILC have its own session at the Canadian #breastcancer symposium! Enjoyed participating with @anaelisalohman1 @nan_nixon @AM_Covelli_MD Patient advocate @lobbccanada (@CBCN @LobularBCA) advocated for this for years, glad this happened before her passing.

Timely @JCO_ASCO commentary on CNS surveillance for MBC by @JerzakKasia et al. Mixed recommendations from international societies, informed by practices that predated novel RT techniques (eg SRS) and brain-active drugs (ADCs, TKI). Urgent call to action. ascopubs.org/doi/pdf/10.120…

The @UofTSurgery community mourns the loss of cherished colleague, Dr. Sean Cleary. "Sean has touched the lives of many of us – as a clinical colleague, teacher, mentor, supervisor, confidential advisor, and friend. . ." Read the Chair's message at surgery.utoronto.ca/news/Sean-Clea…

Drs @tdcil and @DrCBrezden opening the 2025 Canadian Breast Cancer Symposium @uoftcpd #CBCS25

Enjoyed #ASCO25, supporting Rina Lee MS2 @uoftmedicine and breast surgical oncology fellow Richa Jaiswal @UofTGSx presenting their posters, and colleague Joanne Kotsopoulos @WCHResearch give a podium presentation @ASCO! Congrats to Dr Jaiswal on her @ConquerCancerFd merit award!

@SteveCaiMD @BCRFcure @ConquerCancerFd @ASCO @WCHospital @WCHResearch @UofTGSx @UofTSurgery @UofTIMS @ihpmeuoft @uoftmedicine Thanks @SteveCaiMD !! 🙏

@DavidLimMD @BCRFcure @ConquerCancerFd @ASCO @WCHospital @WCHResearch @UofTGSx @UofTSurgery @UofTIMS @ihpmeuoft @uoftmedicine Congrats David!!!

An honour to receive a @BCRFcure-sponsored Career Development Award at the @ConquerCancerFd grants and awards ceremony at #ASCO25 @ASCO Grateful for funding to support my #breastcancer program @WCHospital @WCHResearch @UofTGSx @UofTSurgery @UofTIMS @ihpmeuoft @uoftmedicine

Looking forward to Dr. Osman joining our Breast Surgical Oncology team @WCHospital on July 1st! @UofTGSx @UofTSurgery

🚨 SURGICAL SPECIALIST SERIES 🚨 This month, for our Breast Surgery module, we'll be joined by Dr. Jaime Escallon, a breast surgeon and professor at the University of Toronto 🏥🇨🇦 Dr. Escallon will give an academic talk and clarify the answers to this month's clinical case. 🩸💉 Join us next WEDNESDAY, May 28th at 7 p.m. COL via Zoom and the @ascolcirugia YouTube Channel! 🇨🇴🎥 Find the Zoom and YouTube links in the LinkTree in our bio 📌🎥 #SoMe4Surgery #MedInstagram #GeneralSurgery #CirugiaGeneral #futuroscirujanos #mama #breastsurgery #Breast

#ASCO25 is around the corner, and it’s inspiring to see the growing momentum for #ILC research at major meetings. Just a few years ago, ILC had little to no visibility @ASCO, this year, 7 ILC abstracts will be presented. Here is a brief overview of each: 1. Macroscale Genomic Alterations in Histomolecular ILC [Poster #1049; Jason A. Mouabbi, MD (MD Anderson)] @JAMouabbi @MDAndersonNews Key Findings: Whole-exome sequencing of 617 samples showed unique CNV patterns and enriched APOBEC activity in histomolecular ILC. These tumors had lower HRD but higher TMB compared to NST, suggesting therapeutic vulnerabilities 2. Neoadjuvant Endocrine Therapy (NAET) vs. Chemotherapy (NAC) in Stage II–III ILC [Poster #603; Jason A. Mouabbi (MD Anderson)] @JAMouabbi @MDAndersonNews Key Findings: In this large retrospective study, NAET have shown great promise as a appropriate alternative to NAC in ILC 3. Serial ctDNA Monitoring in Early-Stage HR+/HER2− ILC [Poster #581; Julia Foldi, MD (UPMC)] @JuliaFoldiMD @oesterreichs @Adrianvlee @UPMCnews @MageeWomens Key Findings: In a cohort of 430 patients, longitudinal ctDNA positivity correlated strongly with distant recurrence, with a 31-fold increased risk when ctDNA was positive within 2 years of surgery. PIK3CA was the most frequent co-mutation with CDH1. 4. ALTTO Trial Subgroup Analysis: HER2+ ILC [Poster #542; Guilherme Nader Marta, MD (Dana-Farber)] @GuiNaderMarta @DFCI_BreastOnc Key Findings: Among 61 HER2+ ILC patients from the ALTTO trial, long-term survival outcomes were comparable to NST, but CNS relapse was significantly higher in ILC (13.6% vs. 5.0%), highlighting unique metastatic behavior. 5. Patient Experiences in ILC Diagnosis and Treatment [Poster #11111; Astrid Quirarte (UCSF)] @UCSF Key Findings: Qualitative analysis from a prospective registry revealed diagnostic delays due to mammographically occult disease, misclassification, and underestimation of tumor size, underscoring the need for ILC-specific clinical approaches 6. Impact of Surgery Type on Mortality in Unilateral ILC [Poster @585; Richa Jaiswal, MD (Women’s College Hospital)] @DavidLimMD @WCHospital Key Findings: SEER-based analysis of 58,861 patients found that bilateral mastectomy reduced contralateral breast cancer risk and was associated with a modest but significant reduction in breast cancer mortality compared to lumpectomy 7. Treatment Patterns and Genomic Landscape of Metastatic ILC [Poster #1119; Sherry Shen, MD (MSKCC)] @SherryShenMD @FresiaPareja @jhaveri_komal @MSKCancerCenter Key Findings: In a large single-institution cohort (n=654), OS differed significantly by PIK3CA, PTEN, and CDH1 mutation status, emphasizing the prognostic relevance of NGS in metastatic ILC @LobularBCA @elbcc